FDA Approves First Drug, Brinsupri, for Chronic Lung Condition Bronchiectasis
By I. Edwards HealthDay Reporter
WEDNESDAY, Aug. 13, 2025 — For the first time, people with bronchiectasis will have a treatment option.
The U.S. Food and Drug Administration (FDA) has approved Insmed’s daily pill brensocatib, which will be sold under the brand name Brinsupri.
The drug is designed to treat non-cystic fibrosis bronchiectasis (NCFB), a chronic condition that damages the lungs and makes it harder to clear mucus, the company said in a statement.
The approval comes after the medication succeeded in one of last year’s most closely watched Phase 3 clinical trials. The company says Brinsupri could become a blockbuster, estimating peak sales at $5 billion a year, STAT News reported.
"The FDA approval of the first-ever treatment for non-cystic fibrosis bronchiectasis is a historic milestone for patients and for Insmed," the company’s chief medical officer, Dr. Martina Flammer, said in a statement.
The American Lung Association estimates that bronchiectasis affects between 350,000 and 500,000 adults in the United States.
It happens when the airways in the lungs become widened, thickened and scarred — often after an infection or other damage. This makes it difficult to clear mucus, allowing germs and particles to build up and cause repeated lung infections.
Brinsupri works by blocking an enzyme called DPP1. Insmed bought the drug from AstraZeneca for $30 million and is also testing it for other conditions, such as chronic rhinosinusitis, STAT News reported.
The company plans to sell the drug in the U.S. at an annual list price of $88,000. It has also filed for approval in Europe and the United Kingdom, and it plans to do so in Japan.
"For the first time, we have a treatment that directly targets neutrophilic inflammation and addresses a root cause of bronchiectasis exacerbations. Based on the strength of the data and the impact we've seen in patients, I believe this could become the new standard in non-cystic fibrosis bronchiectasis care." Dr. Doreen Addrizzo-Harris, a pulmonary and critical care physician and director of the NYU Langone Health Bronchiectasis and NTM Program in New York City, said in a news release.
Sources
- Insmed, news release, Aug. 12, 2025
- STAT News, Aug. 12, 2025
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted August 2025
Read this next
California Wildfires May Have Caused Hundreds More Deaths
THURSDAY, Aug. 7, 2025 — Wildfires that tore through Los Angeles early this year may have caused hundreds more deaths than official reports show, new research...
You Might Inhale 68,000 Microplastics Per Day
THURSDAY, July 31, 2025 (HeathDay News) — Scientists say the average person may be inhaling microscopic, lung-penetrating plastic particles at a rate that’s 100 times...
Palliative Care or Hospice? What's the Distinction?
SATURDAY, July 26, 2025 — If a doctor diagnoses you with a serious illness and suggests palliative care, don’t jump to conclusions. It doesn’t mean you have...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.